The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models by Dongli Liu, Cassandra J. Vandenberg, Patrizia Sini, Lorenz Waldmeier, Rosa Baumgartinger, Laura Pisarsky, Georg Petroczi, Gayanie Ratnayake, Clare L. Scott, Caroline E. Ford

Get full text

Farletuzumab ecteribulin and MORAb‐109, folate receptor alpha and mesothelin targeting antibody–drug conjugates, show activity in poor prognosis gynaecological cancer models by Ksenija Nesic, Katherine Rybinski, Gayanie Ratnayake, Gwo‐Yaw Ho, Ratana Lim, Marc Radke, Chloe Neagle, Elizabeth M. Swisher, Matthew J. Wakefield, Holly E. Barker, Keiji Furuuchi, Clare L. Scott, Cassandra J. Vandenberg

Get full text

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer by Michal M Hoppe, Patrick Jaynes, Joanna D Wardyn, Sai Srinivas Upadhyayula, Tuan Zea Tan, Stefanus Lie, Diana G Z Lim, Brendan N K Pang, Sherlly Lim, Joe P S Yeong, Anthony Karnezis, Derek S Chiu, Samuel Leung, David G Huntsman, Anna S Sedukhina, Ko Sato, Monique D Topp, Clare L Scott, Hyungwon Choi, Naina R Patel, Robert Brown, Stan B Kaye, Jason J Pitt, David S P Tan, Anand D Jeyasekharan

Get full text